Financing Malaria: The Global Fund perspective

Slides:

Advertisements

Similar presentations

Operational Research in the context of HIV/AIDS, TB and Malaria control efforts from the perspective and experience of the Global Fund Serge Xueref John.

Advertisements

WHO/WIPO/WTO Meeting Geneva, July 2010 Procurement and Supply Management Approach Monitoring Availability and Pricing WHO/WIPO/WTO technical Symposium.

Track C on prevention issues Recognised Priority technical areas are ITNs, malaria in pregnancy, vector control, including use of DDT epidemics and complex.

The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.

5 th Consultative Stakeholder meeting UN Prequalification of Diagnostics, Medicines and Vaccines 11 Feb 2010 Achievements and Impacts of prequalification.

World Health Organization Department of HIV/AIDS Estimates of ARV Treatment Needs

Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,

NY /020419VtsimSL001 Malaria Advocacy and the Global Fund Update 2006.

APPMG World Malaria Day Event, 2013 Invest in The Future: Defeat Malaria Kolawole Maxwell, Malaria Consortium Nigeria Country Director.

Public Health in Practice Mosquito Nets. Introduction Obviously, a mosquito net offers protection against mosquitoes and other tiny, biting insects. When.

Protection of Basic Services in Ethiopia The World Bank May 2006.

Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.

Public-Private Mix (PPM) for TB Control in Global Fund grants Scope and significance SS Lal *, Mukund Uplekar #, Itamar Katz*, Knut Lonnroth #, Ryuichi.

Clermont-Ferrand, 11 May, 2011 Performance based funding Global Fund to fight AIDS, Tuberculosis and Malaria – progress and challenges Kirsi Viisainen,

Partners in Impact: Innovative Partnerships to fight disease HEI 2008 Daniel Low-Beer, Director Performance, The Global Fund to Fight AIDS, TB and malaria.

Treatment Optimization in Latin America and the Caribbean: How can the GF contribute?

Malaria Landscape 2007 Executive Director's Report to the 13 th Board Meeting.

PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,

The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.

Total health ODA commitments, US$ Billions.

The GEF Replenishment How does it come about? Gustavo Fonseca Head, Natural Resources Biodiversity, International Waters, Land Degradation, SFM/REDD+ Global.

The Global Fund- structure, function and evolution February 18, 2008.

Open Society Institute, Public Health Program Proposal Development and Advocacy Seminar for Eastern and Southern Africa Cape Town, South Africa 18 February.

Analysis of Global Fund Support for Health Systems Strengthening Emily Trautner Geneva, Switzerland October 1, 2010.

INDEPTH Effectiveness and Safety studies of antimalarials in Africa (INESS ) IMPLEMENTATION SO FAR Aziza Mwisongo INDEPTH AGM PUNE, INDIA October 2009.

Suzanne Ehlers, Mercedes Mas de Xaxas, and Felicity Daly RHSC, London/ June 5, 2009 Leveraging Monies for HIV Integration and Prevention.

World Bank Project China Fidelis Demonstration projects Mobilising funding for TB & Poverty Are there effective, implementable strategies?

RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.

TFM Progress Update Malaria Tobgyel, Dy. Chief Programme Officer Vector-borne Disease Control 31st CCM meting, 28th August, 2015.

1 IASC Weekly meeting Geneva, 14 September 2005 Malaria control in emergency settings Charles Delacollette WHO/Roll Back Malaria Department.

Roadmap to Achieve RBM Targets September 2009 – December 2010 Ghana.

Trust Fund for Statistical Capacity Building Progress Report - October 2008 Misha Belkindas TFSCB Consultative Group Meeting November 2008.

Grant Agreement Documents (between Global Fund and Principal Recipient) Workshop for TB Experts Hosted by WHO Stop TB and the Global Fund December 2005.

Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers Core presentation prepared by Sophie.

Green Climate Fund TC Geneva, 9 September 2011 Enhanced Direct Access – The approach of the Global Fund. Katja Roll External Relations and Partnerships.

The Global Fund December JulyG8 endorse new AIDS, TB and malaria targets in Okinawa 2001April June July African leaders commit to greater response.

Roadmap to Achieve RBM Targets September 2009 – December 2010 Malawi.

Global Fund Assessments Part II: Understanding Assessment Results Geneva – December 2005.

Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.

REPORT ON CARICOM/PANCAP GLOBAL FUND ROUND 3 14 TH MEETING OF THE RCM OF PANCAP Christ Church, Barbados March 25-26, 2010.

Global Fund Grants To SOTA Countries NO YR1 ALL Yrs TIER 113 $91 mil $461mil TIER 22 (5) $70 mil $443 mil _________________________________________________________________________.

Establishing a Global Vaccine Development Fund Peter Hale The Foundation for Vaccine Research Washington, DC Consultation on Financing of R&D Preparedness.

Kenya Roadmap to Achieve RBM Targets September 2009 – December 2010.

1 Roadmap to Achieve RBM Targets ERITREA January 2011 – December 2011.

1 Phase 2 Grant Renewals - March A- Overview A.1- Performance-based Funding Y1Y2Y3Y4Y5 Proposal Initial Grant Agreement(s)Extension of Grant.

Next-Generation LLINs: Programmatic Implications Matthew Lynch October 26, 2015.

TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.

Achievements and impacts of WHO prequalification to date MSF perspective Carine Werder MSF international pharmacist coordinator Geneva, 11 th February.

The Bank’s Regional HIV/AIDS Strategies An Overview.

Global Fund: Contributions to the Global Health Workforce 2 – 3 February 2012 Irish Forum for Global Health Conference.

Roadmap to Achieve RBM Targets September 2009 – December 2010 MOZAMBIQUE.

1 Zanzibar Roadmap to Achieve RBM Targets, January 2011 – December 2011.

Fifteenth Board Meeting Geneva, April 2007 Partners in Impact Results Report Global Fund Board Meeting Geneva, April 2007.

Seasonal Malaria Chemoprevention: WHO Policy and Perspectives

An Overview of the Global Fund and its Architecture

AFRICAN RENAISSANCE AND INTERNATIONAL CO-OPERATION FUND ANNUAL REPORT 2015/16 Presentation to Portfolio Committee on International Relations and Cooperation.

WHO Millennium Development Goals Grant Project

Procurement and Supply Management Policies

World Health Organization

Funding the Implementation of the Busan Action Plan for Statistics

iCCM Experience Malawi

Expanding ARV treatment in developing countries: Issues and Prospects

Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.

AFRICAN RENAISSANCE AND INTERNATIONAL CO-OPERATION FUND 2016/17 ANNUAL REPORT (ARF) Presentation to NCOP Select Committee on Trade and International.

World Health Organization

AIDS-related deaths the lowest this century

Partners for Measles Advocacy 7th Annual Meeting

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Long-lasting insecticide-treated net (LLIN) primary scale-up and usage statistics. Long-lasting insecticide-treated net (LLIN) primary scale-up and usage.

How are programmes specifically designed using collected data?

Presentation transcript:

Financing Malaria: The Global Fund perspective NY-070626.001/020419VtsimSL001 Financing Malaria: The Global Fund perspective Vinand Nantulya

Malaria resource needs, 2007

Malaria Grants after 5 Rounds of Global Fund Proposals NY-070626.001/020419VtsimSL001 Malaria Grants after 5 Rounds of Global Fund Proposals US$1.2 Billion for 2 years US$ 2.0 Billion for years 1-5 81 countries 97 components MAL/101005/1

Distribution of malaria grants by region 76%

Projected: Insecticide-treated Nets NY-070626.001/020419VtsimSL001 Projected: Insecticide-treated Nets 108 Million of ITNs to be distributed (total over the lifetime of approved proposals) 44 108 18 40 6 Total ITNs purchased with Round 1 funds Total ITNs purchased with Round 2 funds Total ITNs purchased with Round 3 funds Total ITNs purchased with Round 4 funds Total ITNs purchased by all approved programs PTG/300704/4

Projected: Artemisinin-based treatments NY-070626.001/020419VtsimSL001 Projected: Artemisinin-based treatments 145 Million of artemisinin-based treatments (total over lifetime of approved proposals) 122.8 144.9 Other countries 3.2 10.5 8.4 Sub-Saharan Africa ACT treatments provided with Round 1 funds ACT treatments provided with Round 2 funds ACT treatments provided with Round 3 funds ACT treatments provided with Round 4 funds ACT treatments provided after Rounds 1-4 Retroactive reprogramming of malaria grants is on-going. PTG/300704/5

How are malaria grants performing? ……Assessed performance of 31 grants after two years of implementation Reason: (i) Phase 1 (First 2 years of a grant): Disbursements based on performance against agreed milestones (ii) Phase 2 (end of Phase 1): All grants reviewed for performance against two-year targets to determine if funding can be continued into Phase 2 (years 3-5)

Grant performance was rated as follows… A = 2 Grants achieving or exceeding their targets B1= 18 Satisfactory performance, or with contextual issues that can be resolved B2= 8 Inadequate performance, but have potential to succeed e.g. major recent improvements in program-supporting environment; C = 3 Unacceptably low performance, and with critical contextual risks

Lessons learned Success depends on a package of elements rather than on any single element: Financial resources alone not enough Tools: Better use of existing tools New tools: Drugs, vaccines, insecticides, & DIAGNOSTICS BUT tools alone not enough either Strong health systems (human resources, services, including laboratory diagnostic services, and effective management) Monitoring and evaluation capacity Good governance: public/private/civil society partnership